Markets:

Overview

News

Currencies

International

Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

55.08 -2.21 (-3.86%)

Streaming Delayed Price Updated: 3:35 PM EDT, Jun 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

3 Cash-Producing Stocks with Promising Prospects

November 09, 2025

Free cash flow is one of the most reliable indicators of financial durability. These businesses not only generate cash but reinvest intelligently to sustain momentum.

Via StockStory

This Zimmer Biomet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗

November 06, 2025

Via Benzinga

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗

November 05, 2025

BioMarin presents a strong value investment case with low valuation multiples, robust profitability, and a healthy balance sheet, all while showing solid growth potential.

Via Chartmill

The 5 Most Interesting Analyst Questions From BioMarin Pharmaceutical’s Q3 Earnings Call

November 03, 2025

BioMarin Pharmaceutical’s third quarter results reflected steady top-line growth, with management highlighting enzyme therapies and the Skeletal Conditions business as main contributors. CEO Alexander...

Via StockStory

Topics Earnings

Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday ↗

October 28, 2025

Although the company recorded higher sales overall, it's decided to divest one of its products.

Via The Motley Fool

Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today

October 28, 2025

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 4.5% in the morning session after the company reported third-quarter earnings, which featured a significant earnings miss but a...

Via StockStory

Topics Earnings Economy Government

Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings ↗

October 28, 2025

Via Benzinga

BMRN Q3 Deep Dive: Product Expansion and Portfolio Shifts Define Outlook

October 28, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 4.1% year on year to $776.1 million. The company’s outlook for the full year was...

Via StockStory

BioMarin (BMRN) Q3 2025 Earnings Call Transcript ↗

October 27, 2025

BioMarin (BMRN) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Reports Mixed Q3 2025 Results with Revenue Growth but Earnings Miss ↗

October 27, 2025

BioMarin's Q3 2025 results show mixed performance with revenue growth but a significant earnings miss, while the company raises its full-year outlook.

Via Chartmill

Topics Earnings

BioMarin Pharmaceutical (NASDAQ:BMRN) Posts Q3 Sales In Line With Estimates

October 27, 2025

Via StockStory

BioMarin Pharmaceutical (BMRN) Reports Q3: Everything You Need To Know Ahead Of Earnings

October 25, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be announcing earnings results this Monday after market close. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Earnings Scheduled For October 27, 2025 ↗

October 27, 2025

Via Benzinga

What to Expect from Biomarin Pharmaceutical's Earnings ↗

October 24, 2025

Via Benzinga

3 of Wall Street’s Favorite Stocks to Target This Week

October 24, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

1 Healthcare Stock Worth Investigating and 2 We Question

October 17, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Stocks

1 Mid-Cap Stock to Research Further and 2 That Underwhelm

October 15, 2025

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...

Via StockStory

10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know

October 10, 2025

A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.

Via StockStory

Topics Economy Government World Trade

Is BioMarin Pharmaceutical Inc Gaining or Losing Market Support? ↗

October 09, 2025

Via Benzinga

6 Analysts Assess BioMarin Pharmaceutical: What You Need To Know ↗

October 09, 2025

Via Benzinga

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗

September 29, 2025

BioMarin is a strong value stock with a low P/E ratio, robust financial health, and solid profitability, offering a compelling safety margin for investors.

Via Chartmill

Peering Into BioMarin Pharmaceutical's Recent Short Interest ↗

September 22, 2025

Via Benzinga

2 Profitable Stocks on Our Watchlist and 1 We Turn Down

September 19, 2025

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Via StockStory

Reflecting On Therapeutics Stocks’ Q2 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN)

September 15, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how BioMarin Pharmaceutical...

Via StockStory

Topics Artificial Intelligence

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment ↗

September 08, 2025

BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study.

Via Benzinga

Why BioMarin Pharmaceutical (BMRN) Stock Is Down Today

September 08, 2025

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) fell 2.8% in the morning session after HC Wainwright & Co. initiated coverage on the stock with a Neutral rating and a $60 price target.

Via StockStory

Topics Artificial Intelligence Economy

Forecasting The Future: 5 Analyst Projections For BioMarin Pharmaceutical ↗

September 08, 2025

Via Benzinga

This Duolingo Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗

September 08, 2025

Via Benzinga

2 Growth Stocks to Stash and 1 We Ignore

September 05, 2025

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s...

Via StockStory

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Value Investing Case Study in Undervaluation ↗

September 03, 2025

BioMarin Pharmaceutical (BMRN) is a top value investing pick, trading at a discount with strong financial health, high profitability, and solid growth potential.

Via Chartmill

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.